Cigna plans to shift to a rebate-free model for its commercial pharmacy benefit offerings starting in 2027 that applies discounts upfront at the point of sale. Understanding the potential trade-offs will be key as employers evaluate future benefit strategies.
July 2024
June 2024
FDA Approves Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has approved Kisunla™ (donanemab-azbt, 350mg/20mL injection for IV infusion) as treatment of early symptomatic Alzheimer’s disease (AD) which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.
Medically reviewed by Drugs.com.
By Ernie Mundell HealthDay Reporter
The U.S. Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness.
The FDA has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
FDA Approves Myhibbin Oral Suspension for Prophylaxis of Organ Rejection
Azurity Pharmaceuticals, has announced that the FDA has approved Myhibbin, the only ready-to-use mycophenolate mofetil oral suspension. Mycophenolate mofetil is an antimetabolite immunosuppressant used to protect a donated organ from being rejected from the body’s immune response.